Mantle cell lymphoma (MCL) is a B cell non-Hodgkin's lymphoma, characterized by a poor response to therapy and short survival. To assess the proliferative capacity, we cultured MCL cells, using irradiated 3T6 mouse fibroblasts transfected with human CD40L ('CD40 system') in the presence of different cytokines. Proliferation was measured by ؉ cells are used. In this context IL-10 is a costimulatory factor. IL-10 receptor expression seems to correlate with response to CD40 crosslinking and IL-10. Autocrine IL-10 production might play a role in the proliferation of this lymphoma. This culture system may be useful to test new treatment strategies for this, thus far, therapy-resistant lymphoma.
Introduction
Mantle cell lymphoma (MCL) is a B cell non Hodgkin's lymphoma (NHL) considered to derive from the follicle mantle. 1, 2 Immunophenotyping shows expression of IgM, weak IgD and CD5, without expression of CD10 and CD23. 3, 4 Cytogenetically, a t(11;14)(q13;q32) translocation is found in more than 95%, 5 which juxtaposes the CCND (Bcl-1 locus) oncogene coding for cyclin D1, with the Ig heavy chain locus. 6, 7 The result is an overexpression of cyclin D1, a G1 cyclin. [8] [9] [10] [11] Immunohistochemical detection of cyclin D1 is a useful tool in the differentiation of MCL from other NHL. 12 MCL cells and chronic lymphocytic leukemia (CLL) cells share morphological characteristics and most immunological marker antigens. In this view it is noteworthy that MCL often has a leukemic component, which suggests that MCL cells have comparable homing characteristics. In spite of this resemblance and of the fact that both cell types presumably derive from the follicle mantle, the clinical behavior of MCL is totally different from CLL. Large differences were also found concerning in vitro proliferation capacities upon CD40 stimulation. 13, 14 The CD40 system was initially introduced as a culture system for normal human B lymphocytes. 15 The B cell is activated by stimulation via the CD40 antigen and enters the stage of proliferation. CLL and other indolent B cell malignancies grow very well in the CD40 system, especially if IL-4 is added as a co-stimulatory factor, 14, [16] [17] [18] [19] whereas most MCL cases responded poorly thus far if the CD40 antigen was triggered by a crosslinked anti-CD40 monoclonal antibody. 13, 14 After our observation that IL-10, amongst a series of cytokines, had a stimulatory effect on the growth of a few cases of MCL in the CD40 system, we investigated its role in a larger series. Moreover, we used the modified CD40 system by applying CD40 ligand (CD40L) as crosslinking agent.
Materials and methods

Cells
MCL cells from 16 patients were obtained from blood, lymph nodes, pleural fluid or spleens after Ficoll-Isopaque (1077 g/ml) density gradient centrifugation and cryopreserved in 10% dimethylsulfoxide until further study. The diagnosis was established by cytomorphological assessment of the blood; histological examination of lymph nodes, spleen and bone marrow; immunophenotyping, molecular and cytogenetic analysis, 20 following the criteria of the REAL classification. 21 After thawing, residual T cells were removed with help of magnetic immunobeads. Cell suspensions were incubated with saturating amounts of anti-CD2 and anti-CD3 (antileu5b and anti-leu4, Becton Dickinson, Mountain View, CA, USA) monoclonal antibodies (mAbs) followed by incubation with sheep-anti-mouse-coated magnetic beads according to the description of the manufacturer (Dynabeads; Dynal, Oslo, Norway). After immunomagnetic separation the suspensions always contained less than 0.5% CD2 + T cells as was confirmed by flow cytometry.
IL-10 receptor expression
IL-10 receptor protein was measured using a mouse antihuman IL-10 receptor antibody (R&D Systems Europe Ltd, Abingdon, UK), which was subsequently detected using a phycoerythrin (PE) labeled goat anti-mouse antibody (Southern Biotechnology Associates, Birmingham, UK). As a positive control Burkitt lymphoma cells were used. 22 
Culture system
Five thousand and 50 000 irradiated (70 Gy) 3T6 cells transfected with the human CD40L (a kind gift of Dr M Bakkus, Brussels 23 ) were added in round-bottom 96-well or in flat Immunofluorescence preparations of light chain expression before (left) and after (right) culture of case 1. FITC labeling of the light chain. bottom 24-well culture plates (Costar, Becton Dickinson), respectively. T cell-depleted malignant B cells were added, 10 5 in 96-well or 10 6 in 24-well plates, in a final volume of 100 l or 1000 l, respectively. Complete culture medium consisted of IMDM (Gibco Laboratories, Grand Island, NY, USA), 5.6% heat inactivated fetal calf serum, 0.56% human serum albumin (CLB, Amsterdam, The Netherlands), 45 g/ml human transferrin (Behring, Mannheim, Germany), 0.01 mmol/1 beta-mercaptoethanol (Sigma Chemical, St Louis, MO, USA), 5.5 g/ml bovine insulin (Sigma), penicillin/streptomycin (20 U/ml and 20 g/ml respectively, Gibco) and 1% glutamine (Gibco). Human recombinant (HuR) IL-10 (CLB) was added at different concentrations. HuR IL-1 (Sclavo, Siena, Italy) was added at a final concentration of 2 ng/ml; HuR IL-2 (Roussel, Paris, France) at a final concentration of 100 U/ml; HuR IL-4 (Schering-Plough, Kenilworth, NJ, USA) at a final concentration of 5 ng/ml; HuR IL-6 (Sandoz, Basel, Switzerland) at a final concentration of 2 ng/ml; HuR G-CSF (Amgen, Thousand Oaks, CA, USA) at a final concentration of 10 ng/ml; HuR GM-CSF (Sandoz, Basel, Switzerland) at a final concentration of 1 ng/ml.
Cells were cultured in a fully humidied 5% CO 2 atmosphere at 37°C for 7 days. For the last 18 h of culture, 3 H-thymidine 1Ci/well was added. Cells were harvested and counts per minute (c.p.m.) were determined on a liquid scintillation spectrometer. All results were expressed as means of six replicate wells; standard deviation was less than 10%. As correction for background, 3 H-thymidine incorporation by irradiated murine fibroblasts only was subtracted from the final counts obtained. IL-10 receptor blocking was performed using a monoclonal anti-human IL-10R antibody (R&D Systems) added to the culture medium throughout the whole culture period at different concentrations varying from 0.1 ng/ml to 5 g/ml. IL-10 was directly blocked by an anti-human IL-10 antibody (R&D Systems) added during culture and used at concentrations ranging from 1 ng to 1 g/ml.
Analysis of the cultured cells
After mechanical disruption of the cells from the fibroblast layer, cytospin preparations were made on day 7 for morphological assessment by May-Grünwald-Giemsa staining, and for assessment of the presence of immunoglobulin heavy and light chains (FITC-and TRITC-labelled polyclonal antibodies goat antihuman Ig anti-, anti-␦, anti-␣, anti-␥ from Nordic, Tilburg, The Netherlands; goat anti-human Ig anti-from Kallestad Laboratories, Chaska, MN, USA, and rabbit anti-human Ig anti-from Dakopatts, Glostrup, Denmark). Flow cytometry of the cultured cells was performed using FITC or PE labeled mAbs with reactivity against CD2, CD3, CD5, CD19, CD20, CD40 and CD138 to confirm the nature of the lymphoma cells, to exclude overgrowth of residual normal T and B cells and to investigate differentiation of the cultured cells. Controls with unlabeled cells and IgG1 mAbs were always included to rule out aspecific fluorescence. Analysis was performed on a FACScan (Beckton Dickinson) using LDS-751 to select for viable cells. 24 Results were analyzed using the CellQuest software (BD).
Cell division analysis
To analyze the number of cell divisions during the culture period, cells were incubated with 5-(and-6)-carboxyfluorescein diacetate, succinimidyl esther (5(6)-CFDA, SE or CFSE, Molecular Probes Europe BV, Leiden, The Netherlands) at a concentration of 2.5 M for 10 min at 37°C. 25 The reaction was stopped using fetal calf serum. Cell suspensions were washed before culture. Analysis of the cultured cells was done after 6 and 9 days on a FACSCalibur (BD).
Detection of autocrine IL-10 production during culture
Culture supernatants were harvested after 7 days. To measure IL-10 concentrations, an enzyme linked immunosorbent assay (ELISA) was performed according to the standard procedure of the CLB.
Epstein-Barr virus (EBV) analysis
EBV expression was assessed by hybridization on slides using a fluoresceine conjugated EBER PNA probe (Y5200, Dako, Copenhagen, Denmark).
Results
In the first few days of culture, small clusters of MCL cells were formed adherent to the fibroblasts, whereas in the absence of CD40L expressing fibroblasts no such aggregates were seen. After 1 week, the majority of MCL cells had 
Proliferation analysis with and without additional cytokines
Thirteen out of 16 MCL cases proliferated well with a 3 Hthymidine incorporation ranging from 4229 to 57 180 c.p.m. (Figure 2 ). In 10 of these CD40-responsive cases an additional response upon addition of IL-10 (20 ng/ml) was seen (range 117-376% of the counts with CD40L only). IL-10 only without CD40 crosslinking did not stimulate proliferation in all but one of the nine cases tested. IL-4 had an additional effect on 3 H-thymidine uptake in only four cases, whereas in 10 other no or even a markedly inhibitory effect was seen (Figure 2) .
Cells of nine cases were also cultured in the presence of CD40L fibroblasts and a panel of other cytokines or combinations of these cytokines with IL-10 ( Figure 3) . The cytokines were used at suboptimal concentrations with IL-10 also at a suboptimal concentration of 2 ng/ml, to obtain information on synergistic activity. IL-1 inhibited proliferation in three cases (cases 2, 5 and 7). IL-2, G-CSF and GM-CSF did not significantly alter the proliferative response. IL-6 had a co-stimulatory effect in cases 4 and 8. There was no synergistic growth Leukemia induction nor inhibition by combinations of IL-10 with these cytokines (data not shown). The three MCL cases that did not proliferate in the CD40 system were not responding upon any additional other cytokine either.
Dose-response relationship of IL-10
MCL cells of two cases were cultured in the CD40 system with different concentrations of IL-10 (from 0.2 to 80 ng/ml) and harvested on day 7. IL-10 at a concentration of 0.2 ng/ml had no detectable effect on proliferation, at 2 ng/ml enhanced proliferation was seen and a plateau was reached at a concentration of 20 ng/ml (data not shown).
Cell division monitoring by CFSE-staining
CFSE-labeled cells exhibit a single sharp log-normal distribution of fluorescence intensity, the mean of which is diluted two-fold with each consecutive cell division. 25, 26 Case 3 was incubated with CFSE according to the method of Lyons and Parish 25 and cultured for 9 days. After 6 days, cell divisions could be visualized, and after 9 days a series of divisions had taken place, especially when IL-10 was added to the culture medium (Figure 4) .
Mechanisms of the proliferative capacity of IL-10
We pre-incubated lymphoma cells of cases 1, 4 and 10 for 1 h with IL-10 (20 ng/ml), washed the cells and cultured them in the CD40 system without further IL-10. In comparison with cells not pre-incubated, cases 1 and 4 had a significant rise in 3 H-thymidine uptake after pre-incubation, whereas case 10 showed no difference in proliferation. When we added IL-10 not before day 6 of the culture, there was a rise in 3 Hthymidine uptake for case 1 and a minor increase for cases 4
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Figure 3
Incorporation of 3 H-thymidine after a 7-day culture period of MCL cells upon CD40 stimulation in combination with a panel of other cytokines: IL-1, IL-2, IL-6, G-CSF and GM-CSF.
Figure 4
CFSE staining of MCL case 3 during a 9-day culture period. CFSE is equally distributed after each cell division resulting in a proportional decrease in fluorescence intensity. Note the increased number of cell divisions in the cell population cultured in the presence of IL-10. and 10. However, in none the maximal proliferation level was reached compared to the presence of IL-10 during the whole culture period. Data are shown in Table 1 .
In four cases IL-10R expression was measured during 1 week of culture in the CD40 system. The data are shown in Figure 5 . Notably, the case that responded most strikingly to addition of IL-10 (case 4) had IL-10R expression only in the beginning of the culture. Case 1, a good responder to IL-10 in all settings, had a high expression of IL-10R throughout the culture period. Case 14, the non-responder in the CD40 system had no measurable expression of IL-10R.
Autocrine IL-10 production
In the supernatants of 10 cases, cultured with CD40L expressing fibroblasts in the absence of any cytokine, IL-10 concentrations were measured at the end of the culture period. The Table 2 IL-10R blocking and autocrine IL-10 production results are shown in Table 2 . In eight out of 10 cases IL-10 production was found.
IL-10 receptor blocking
To measure the influence of exogenous and autocrine IL-10 production during the culture period, we measured 3 Hthymidine incorporation after blocking of the IL-10 receptor in seven cases. From control experiments, we know that an antibody concentration of 1.0 g/ml could almost completely block the activity of IL-10 at a concentration of 20 ng/ml. We observed decreased proliferation (from 14 to 47%) after IL-10R blocking in four cases, resulting in 3 H-thymidine counts below the level of CD40-stimulation alone. However, no clear relationship between autocrine IL-10 levels and IL-10R blocking could be seen.
MCL and EBV
EBV-infected cells can show an increased production of IL-10, probably due to homology of the IL-10 DNA and the EBV BCRF1 genome. 27 To assess the role of EBV in MCL we measured EBV RNA in six cases. No positive signals were found (data not shown).
Isotype switching during culture
Because IL-10 is a well known immunoglobulin switch factor, 28 we investigated immunoglobulin expression in five cases before and after culture. The addition of IL-10 to the cultures did not alter the immunophenotype of the cells. There was no difference in the expression of membrane-bound IgM before and after culture. Switching to IgG or IgA was never observed.
Discussion
We have shown that MCL cells can be cultured upon CD40 crosslinking and that additional IL-10 induces further cell proliferation in the majority of cases. In previous experiments when Leukemia CD32 transfected ltk − murine fibroblasts with CD40 mAbs as 'CD40 system' were used, CD40 stimulation of MCL appeared less successful. 13, 14 Stimulation of the CD40 antigen via crosslinked CD40 mAbs is apparently less effective than via a CD40L expressing cell line. Moreover, we cannot exclude that differences between the murine fibroblasts (ltk − vs 3T6) also play a role in the induction of proliferation. We have shown in previous experiments with myeloma cells that the mere presence of non-transfected murine fibroblasts can induce proliferation of malignant B cells. This proliferation could be blocked in some cases by anti-IL-6 antibodies. 14 The selection of fibroblasts, however, does not seem to play an important role in the present study because none of five MCL cases tested proliferated upon non-transfected 3T6 fibroblasts alone (data not shown).
The mechanism of the proliferation in the CD40 system and the stimulation by IL-10 is not yet clarified. We did not find a difference in CD40 expression between responding and nonresponding cases and it appears that IL-10, in contrast to IL-4, 15, 23 plays no important role in upregulating this expression. Pre-incubation with IL-10 stimulated the proliferation in two of three cases, which suggests that IL-10 influences the CD40-CD40L interaction via the IL-10 receptor or that there is an independent effect on survival of the mantle cells.
In spite of careful depletion maneuvers upfront, 3 H-thymidine incorporation could have been caused by contaminating proliferating normal B and T cells. Therefore, we performed an experiment using CFSE staining. The IL-10-dependent proliferation is nicely illustrated with the whole population showing a homogeneous shift to the left. The combination of these results and the clonality analysis by / staining are strongly suggestive of merely monoclonal proliferation.
Blocking of the IL-10 receptor in the absence of exogenous IL-10 had an inhibitory effect on the proliferation of several cases, which however could not be related to autocrine production of IL-10 by the mantle cells. Presumably, the measurement of 3 H-thymidine at one moment in this culture period reflects an insensitive approach. We could not demonstrate any switching of the isotype in the MCL cells. Apparently, IL-10 did not function as a switch factor as it does in normal B cells and in CLL cells. [28] [29] [30] It remains unclear why such a difference between the in vitro proliferation pattern of CLL cells and MCL is seen. We and others 14, 17, 18 found that the large majority of CLL cases proliferated upon CD40 crosslinking if additional IL-4 was present. In contrast, IL-4 exerted an inhibitory effect in many MCL cases. These growth differences do not explain the clinical course of both malignancies, CLL being an indolent disease with a long median overall survival and MCL being an aggressive lymphoma with a median survival time of less than 3 years.
The strong in vitro response to IL-10 in this culture system may eventually lead to a better understanding of the proliferation of MCL and may help the testing of novel therapeutic strategies.
